Journal of Cardiac Failure
Volume 17, Issue 4 , Pages 272-281 , April 2011

Effects of Intracoronary Stem Cell Transplantation in Patients With Dilated Cardiomyopathy

  • Bojan Vrtovec, MD, PhD

      Affiliations

    • Advanced Heart Failure and Transplantation Center, Ljubljana, Slovenia
    • Corresponding Author InformationReprint requests: Bojan Vrtovec, MD, PhD, Advanced Heart Failure and Transplantation Center, Department of Cardiology, Ljubljana University Medical Center, Zaloska 7, Ljubljana, Slovenia. MC SI-1000, Ljubljana. Tel: (+3861)522-2844; Fax: (+3861)522-2828.
    • ,
  • Gregor Poglajen, MD

      Affiliations

    • Advanced Heart Failure and Transplantation Center, Ljubljana, Slovenia
    • ,
  • Matjaz Sever, MD

      Affiliations

    • Department of Hematology, Ljubljana, Slovenia
    • ,
  • Luka Lezaic, MD

      Affiliations

    • Center for Nuclear Medicine, Ljubljana, Slovenia
    • ,
  • Dragoslav Domanovic, MD, PhD

      Affiliations

    • Blood Transfusion Center of the Republic of Slovenia, Ljubljana, Slovenia
    • ,
  • Peter Cernelc, MD, PhD

      Affiliations

    • Department of Hematology, Ljubljana, Slovenia
    • ,
  • François Haddad, MD

      Affiliations

    • Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA
    • ,
  • Guillermo Torre-Amione, MD, PhD

      Affiliations

    • Hospital San José TEC de Monterrey, Monterrey, Mexico
    • Weill Medical College of Cornell University, New York, NY
    • Methodist DeBakey Heart Center at The Methodist Hospital, Houston, TX

Received 10 February 2010 ,Revised 1 November 2010 ,Accepted 11 November 2010.

References 

  1. Collins SD, Baffour R, Waksman R. Cell therapy in myocardial infarction. Cardiovasc Revasc Med. 2007;8:43–51
  2. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167:989–997
  3. Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, Lehmann R, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355:1222–1232
  4. Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation. 2005;112:1128–1135
  5. Guarita-Souza LC, Carvalho KA, Woitowicz V, Rebelatto C, Senegaglia A, Hansen P, et al. Simultaneous autologous transplantation of cocultured mesenchymal stem cells and skeletal myoblasts improves ventricular function in a murine model of Chagas disease. Circulation. 2006;114(1 Suppl):I120–I124
  6. Kaski JP, Elliott P. ESC Working Group. The classification concept of the ESC Working Group on myocardial and pericardial diseases for dilated cardiomyopathy. Herz. 2007;32:446–451
  7. Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JG. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J. 2005;26:778–793
  8. Vrtovec B, Starc V, Starc R. Beat-to-beat QT interval variability in coronary patients. J Elecardiol. 2000;33:119–125
  9. Berger RD, Kasper EK, Baughman KL, Marban E, Calkins H, Tomaselli GF. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation. 1997;96:1557–1565
  10. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Loffler H, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol. 1994;87:609
  11. Nair M, Mukherjee S, Ahluwalia NS, Vaid AK, Kumar N. Feasibility and safety of autologous intracoronary stem cell transplantation in patients of non ischemic dilated cardiomyopathy. Indian Heart J. 2007;59:511–514
  12. Silva GV, Perin EC, Assad JA. Transendocardial injection of autologous bone marrow mononuclear cells may enhance myocardial viability around cell injection site. J Am Coll Cardiol. 2004;43:814–821
  13. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294–2302
  14. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27:2775–2783
  15. Fischer-Rasokat U, Assmus B, Seeger FH, Honold J, Leistner D, Fichtlscherer S, et al. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail. 2009;2:417–423
  16. Valgimigli M, Rigolin GM, Fucili A, Porta MD, Soukhomovskaia O, Malagutti P, et al. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation. 2004;110:1209–1212
  17. Goussetis E, Manginas A, Koutelou M, Peristeri I, Theodosaki M, Kollaros N, et al. Intracoronary infusion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution. Stem Cells. 2006;24:2279–2283
  18. Blocklet D, Toungouz M, Berkenboom G, Lambermont M, Unger P, Preumont N, et al. Myocardial engraftment of nonmobilized peripheral-blood CD34+ cells after intracoronary injection. Stem Cells. 2006;24:333–336
  19. Theiss HD, David R, Engelmann MG, Barth A, Schotten K, Naebauer M, et al. Circulation of CD34+ progenitor cell populations in patients with idiopathic dilated and ischaemic cardiomyopathy (DCM and ICM). Eur Heart J. 2007;28:1258–1264
  20. Torre-Amione G, Vooletich MT, Farmer JA. Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs. 2000;59:745–751
  21. Terada N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature. 2002;416:542–545
  22. Ebelt H, Jungblut M, Zhang Y, Kubin T, Kostin S, Technau A, et al. Cellular cardiomyoplasty: improvement of left ventricular function correlates with the release of cardioactive cytokines. Stem Cells. 2007;25:236–244
  23. Chang MG, Tung L, Sekar RB, Chang CY, Cysyk J, Dong P, et al. Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation. 2006;113:1832–1841
  24. Dhein S, Garbade J, Rouabah D, Abraham G, Ungemach FR, Schneider K, et al. Effects of autologous bone marrow stem cell transplantation on beta-adrenoceptor density and electrical activation pattern in a rabbit model of non-ischemic heart failure. J Cardiothorac Surg. 2006;1:17
  25. Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet JM, Turney J, et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J. 2009;30:2722–2732
  26. Ripa RS, Jorgensen E, Wang Y, Thune JJ, Nilsson JC, Sondergaard L, et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation. 2006;113:1983–1992

 Clinical Trial Registration Information: Clinicaltrials.gov identifier: NCT00629018.

 See page 280 for disclosure information.

PII: S1071-9164(10)01216-9

doi: 10.1016/j.cardfail.2010.11.007

Journal of Cardiac Failure
Volume 17, Issue 4 , Pages 272-281 , April 2011

Article Tools

* Image Usage & Resolution